Many of the most important developments in modern biotechnology are based on short DNA or RNA molecules, called Oligonucleotides. From basic research and diagnostics like PCR reactions to gene therapy like CRISPR/Cas-systems, the biotech revolution runs on nucleic acids, and oligonucleotides are at its core. For modern medicine, it means diverse diseases can be treated or even cured at the most fundamental level.
Bridging Science and Application
Once a target sequence is known, a matching oligonucleotide can be designed. Subsequent manufacturing can be scaled up quickly by employing robust platform technologies that demand specialized expertise and experience. As manufacturing, analytics, and delivery continue to evolve, their therapeutic potential will only expand. Ideas turn into molecules – and molecules into medicines.
Driving a New Era of Medicine
In the last decade, more oligonucleotide-based drugs have reached clinical approval than ever before: 24 oligonucleotide therapeutics have been approved as commercial treatments while the total number of oligonucleotide-based assets in the pipeline of international biotech and pharma companies now counts more than 2.500.
Why It Matters
Oligonucleotides are no longer a niche technology. They are part of the core toolkit of modern biotech and medicine. And we at BioSpring are thrilled to contribute to their current and future success, by literally connecting and moving the elements of life.